All News
Upadacitinib Clinical Efficacy in Psoriatic Arthritis
McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.
Read Article
Dr. John Cush RheumNow ( View Tweet)
Inflammatory Conditions Up the Risk of Premature Myocardial Infarction
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Read Article
Aortic Calcification and Lumbar Fracture Risk in Older Men
Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture i
Read Article
RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Panel Rejects Tanezumab for Osteoarthritis
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.
Read Article
Safety of Paternal DMARD or Biologic Use
A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.
Read Article
RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout
Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.
Read Article
Liver Management in Rheumatoid Arthritis - RNL2021 Highlight
While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.
Read Article
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
Links:
RheumNow Podcast – Great Associations (3.19.2021)
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Read Article
Are You a Super Rheum?
Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective" about what disorders and diseases they would treat or just be a generalist.
Read Article
Apremilast Equals MTX in Palmoplantar Psoriasis
Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.
Read Article
Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
JAMA Dermatology has published a Danish national cohort study showing that potent topical corticosteroid use was associated with an increased risk of osteoporosis and major osteoporotic fractures with a dose-response association for cumulative use.
Read Article